RLY-2608
RLY-2608 is a potent and selective inhibitor of mutant PI3Kα. It demonstrates anti-tumor activity in PIK3CA-mutant xenograft models, supporting its use in preclinical oncology research for studying PI3K pathway-driven cancers both in vitro and in vivo.
Product Specifications
CAS Number
2733573-94-7
Product Name Alternative
RLY 2608, RLY2608, PI3Kα, Zovegalisib
Field of Research
Signal Transduction
Purity
98.62% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:5 mg/mL (8.21 mM) ; DMSO:80 mg/mL (131.38 mM)
Smiles
N (C (=O) C1=CC (C (F) (F) F) =CC (F) =C1) C2=C3[C@@H] (NC (=O) C3=CC (=C2) C4=C (C#N) N5C (C=C4) =NC=N5) C6=C (Cl) C=CC (F) =C6
Molecular Formula
C29H14ClF5N6O2
Molecular Weight
608.91
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
